TNXP - Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human
TNXP - Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. - Click For Release
Story updates
11:02:04 AM UTC
SquawkNews
TNXP Tonix Pharmaceuticals announces positive minutes from type C FDA meeting to discuss Adaptive phase 2 field study of tnx-4800, a human, anti-ospa monoclonal antibody, to prevent lyme disease in the U.S. Tonix Pharmaceuticals - plans to start phase 2 tnx-4800 study in Q1 2027 - Majority of enrollment expected in 2028 season, may continue into 2029
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.